GB202117016D0 - New pharmaceutical device - Google Patents

New pharmaceutical device

Info

Publication number
GB202117016D0
GB202117016D0 GBGB2117016.2A GB202117016A GB202117016D0 GB 202117016 D0 GB202117016 D0 GB 202117016D0 GB 202117016 A GB202117016 A GB 202117016A GB 202117016 D0 GB202117016 D0 GB 202117016D0
Authority
GB
United Kingdom
Prior art keywords
new pharmaceutical
pharmaceutical device
new
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2117016.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orexo AB
Original Assignee
Orexo AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orexo AB filed Critical Orexo AB
Priority to GBGB2117016.2A priority Critical patent/GB202117016D0/en
Publication of GB202117016D0 publication Critical patent/GB202117016D0/en
Priority to MX2024006403A priority patent/MX2024006403A/es
Priority to CA3238847A priority patent/CA3238847A1/en
Priority to IL313016A priority patent/IL313016A/en
Priority to CA3238850A priority patent/CA3238850A1/en
Priority to TW111145222A priority patent/TW202333658A/zh
Priority to MX2024006188A priority patent/MX2024006188A/es
Priority to EP22813699.0A priority patent/EP4237051A1/en
Priority to PCT/GB2022/052996 priority patent/WO2023094826A1/en
Priority to PCT/GB2022/052983 priority patent/WO2023094816A1/en
Priority to CN202280078148.XA priority patent/CN118678979A/zh
Priority to EP22814495.2A priority patent/EP4236921A1/en
Priority to CN202280077963.4A priority patent/CN118695851A/zh
Priority to JP2024530530A priority patent/JP2024541470A/ja
Priority to IL313014A priority patent/IL313014A/en
Priority to KR1020247018846A priority patent/KR20240103005A/ko
Priority to JP2024530531A priority patent/JP2024542520A/ja
Priority to KR1020247019617A priority patent/KR20240111769A/ko
Priority to AU2022395920A priority patent/AU2022395920A1/en
Priority to AU2022395916A priority patent/AU2022395916A1/en
Priority to ARP220103244A priority patent/AR127780A1/es
Priority to US18/323,101 priority patent/US11957647B2/en
Priority to US18/323,115 priority patent/US12303472B2/en
Priority to US18/592,846 priority patent/US12472154B2/en
Priority to ZA2024/03890A priority patent/ZA202403890B/en
Priority to US19/189,960 priority patent/US20250262174A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/02—Sprayers or atomisers specially adapted for therapeutic purposes operated by air or other gas pressure applied to the liquid or other product to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/0007—Special media to be introduced, removed or treated introduced into the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fire-Extinguishing By Fire Departments, And Fire-Extinguishing Equipment And Control Thereof (AREA)
GBGB2117016.2A 2021-11-25 2021-11-25 New pharmaceutical device Ceased GB202117016D0 (en)

Priority Applications (26)

Application Number Priority Date Filing Date Title
GBGB2117016.2A GB202117016D0 (en) 2021-11-25 2021-11-25 New pharmaceutical device
ARP220103244A AR127780A1 (es) 2021-11-25 2022-11-25 Nueva composición farmacéutica que comprende adrenalina
CN202280077963.4A CN118695851A (zh) 2021-11-25 2022-11-25 包含肾上腺素的药物组合物
IL313014A IL313014A (en) 2021-11-25 2022-11-25 Pharmaceutical device for use in intranasal administration
IL313016A IL313016A (en) 2021-11-25 2022-11-25 A pharmaceutical preparation that includes adrenaline
CA3238850A CA3238850A1 (en) 2021-11-25 2022-11-25 Pharmaceutical composition comprising adrenaline
TW111145222A TW202333658A (zh) 2021-11-25 2022-11-25 包含腎上腺素之新穎醫藥組合物
MX2024006188A MX2024006188A (es) 2021-11-25 2022-11-25 Nueva composicion farmaceutica que comprende adrenalina.
EP22813699.0A EP4237051A1 (en) 2021-11-25 2022-11-25 Pharmaceutical device for use in intranasal administration
PCT/GB2022/052996 WO2023094826A1 (en) 2021-11-25 2022-11-25 Pharmaceutical composition comprising adrenaline
PCT/GB2022/052983 WO2023094816A1 (en) 2021-11-25 2022-11-25 Pharmaceutical device for use in intranasal administration
CN202280078148.XA CN118678979A (zh) 2021-11-25 2022-11-25 用于在鼻内施用中使用的药物装置
EP22814495.2A EP4236921A1 (en) 2021-11-25 2022-11-25 Pharmaceutical composition comprising adrenaline
MX2024006403A MX2024006403A (es) 2021-11-25 2022-11-25 Dispositivo farmaceutico para uso en administracion intranasal.
JP2024530530A JP2024541470A (ja) 2021-11-25 2022-11-25 アドレナリンを含む医薬組成物
CA3238847A CA3238847A1 (en) 2021-11-25 2022-11-25 New pharmaceutical device for use in intranasal administration
KR1020247018846A KR20240103005A (ko) 2021-11-25 2022-11-25 아드레날린을 포함하는 약학적 조성물
JP2024530531A JP2024542520A (ja) 2021-11-25 2022-11-25 鼻腔内投与における使用のための新しい医薬デバイス
KR1020247019617A KR20240111769A (ko) 2021-11-25 2022-11-25 비강내 투여에 사용되는 새로운 약학적 장치
AU2022395920A AU2022395920A1 (en) 2021-11-25 2022-11-25 Pharmaceutical composition comprising adrenaline
AU2022395916A AU2022395916A1 (en) 2021-11-25 2022-11-25 Pharmaceutical device for use in intranasal administration
US18/323,115 US12303472B2 (en) 2021-11-25 2023-05-24 Pharmaceutical device for use in intranasal administration
US18/323,101 US11957647B2 (en) 2021-11-25 2023-05-24 Pharmaceutical composition comprising adrenaline
US18/592,846 US12472154B2 (en) 2021-11-25 2024-03-01 Pharmaceutical composition comprising adrenaline
ZA2024/03890A ZA202403890B (en) 2021-11-25 2024-05-20 Pharmaceutical composition comprising adrenaline
US19/189,960 US20250262174A1 (en) 2021-11-25 2025-04-25 New pharmaceutical device for use in intranasal administration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2117016.2A GB202117016D0 (en) 2021-11-25 2021-11-25 New pharmaceutical device

Publications (1)

Publication Number Publication Date
GB202117016D0 true GB202117016D0 (en) 2022-01-12

Family

ID=79602091

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2117016.2A Ceased GB202117016D0 (en) 2021-11-25 2021-11-25 New pharmaceutical device

Country Status (11)

Country Link
US (2) US12303472B2 (https=)
EP (1) EP4237051A1 (https=)
JP (1) JP2024542520A (https=)
KR (1) KR20240111769A (https=)
CN (2) CN118695851A (https=)
AU (1) AU2022395916A1 (https=)
CA (1) CA3238847A1 (https=)
GB (1) GB202117016D0 (https=)
IL (1) IL313014A (https=)
MX (1) MX2024006403A (https=)
WO (1) WO2023094816A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3962455T (pt) 2020-05-18 2022-10-13 Orexo Ab Nova composição farmacêutica para entrega de fármacos
US12414916B2 (en) 2021-06-10 2025-09-16 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
AR127780A1 (es) 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina
TW202502309A (zh) * 2023-05-31 2025-01-16 瑞典商奥瑞克索股份公司 包含腎上腺素激導性受體調節劑的噴霧乾燥之組合物
US20260108686A1 (en) 2024-10-21 2026-04-23 Belhaven BioPharma Inc. Compositions, devices, and methods for intranasal delivery of dry powder epinephrine

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702362A (en) 1995-05-26 1997-12-30 Bayer Aktiengesellschaft Nasal applicator
US6398074B1 (en) 1998-03-10 2002-06-04 Valois S.A. Reservoir, reservoir filling method and device for dispensing fluid contained in the reservoir
US20050001411A1 (en) 2001-09-06 2005-01-06 Christian Theiss Method for the determination of parameters of a seat passenger
US6938798B2 (en) 2000-12-08 2005-09-06 Tebro S.A. Fluid or powdery product dispensing device
US7722566B2 (en) 2003-10-09 2010-05-25 Shin Nippon Biomedical Laboratories, Ltd. Device to deliver a powdery medicine into nasal cavity
WO2010142696A1 (en) 2009-06-11 2010-12-16 Charité - Universitätsmedizin Berlin Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
US20110045088A1 (en) 2009-07-31 2011-02-24 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
US7947742B2 (en) 2002-06-28 2011-05-24 Civitas Therapeutics, Inc. Inhalable epinephrine
WO2014004400A2 (en) 2012-06-28 2014-01-03 The Governt. Of The Usa As Represented By The Secretary Of The Department Of Health & Human Services Nasal dry powder delivery system for vaccines and other treatment agents
US9724713B2 (en) 2013-07-05 2017-08-08 Aptar France Sas Fluid or powdery product dispensing device
US20180092839A1 (en) 2016-10-03 2018-04-05 Lance L. Gooberman Medicated spray for treatment of substance abuse, overdose, addiction and impulse control disorders
WO2019038756A1 (en) 2017-08-20 2019-02-28 Solubest Ltd. DRY POWDER COMPOSITIONS FOR INTRANASAL DELIVERY
US10653690B1 (en) 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery

Family Cites Families (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759520A (fr) 1969-11-28 1971-04-30 Aspro Nicholas Ltd Compositions d'aspirine
US5082669A (en) 1989-07-20 1992-01-21 Dainippon Pharmaceutical Co., Ltd. Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked
SE8904296D0 (sv) 1989-12-21 1989-12-21 Pharmacia Ab Transdermal system
ATE196427T1 (de) 1993-12-06 2000-10-15 Takeda Chemical Industries Ltd Zusammensetzung mit verbesserter wasserlöslichkeit, enthaltend eine wasserunlösliche oder an wasser schwerunlösliche verbindung
CH689139A5 (de) 1995-04-03 1998-10-30 Cerbios Pharma Sa Verfahren zur Herstellung einer liposomalen, in Wasser dispergierbaren, oral zu verabreichenden, festen, trockenen therapeutischen Formulierung.
JP3422775B2 (ja) 1998-07-08 2003-06-30 キリン−アムジエン・インコーポレーテツド 高分子医薬品含有粉末状経粘膜投与製剤
JP2000178184A (ja) 1998-12-17 2000-06-27 Lion Corp 粒状組成物、錠剤及び粒状組成物の製造方法
GB9908921D0 (en) 1999-04-19 1999-06-16 Britannia Pharmaceuticals Ltd Spray dispenser for opiod antagonists
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
GB0003782D0 (en) 2000-02-17 2000-04-05 Dumex Ltd As Process
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
KR20010107754A (ko) 2000-05-26 2001-12-07 민경윤 경구투여용 속용정의 제조 방법
IN192750B (https=) 2000-12-15 2004-05-15 Ranbaxy Lab Ltd
US6443152B1 (en) * 2001-01-12 2002-09-03 Becton Dickinson And Company Medicament respiratory delivery device
ITMI20012174A1 (it) 2001-10-18 2003-04-18 Univ Parma Polvere per somministrazione nasale di farmaci
FR2834212B1 (fr) 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
GB0201367D0 (en) 2002-01-22 2002-03-13 Ml Lab Plc Composition
AU2006207868A1 (en) * 2002-03-20 2006-09-28 Alkermes, Inc. Method and apparatus for producing dry particles
WO2004054511A2 (en) 2002-12-13 2004-07-01 The Regents Of The University Of California Analgesic combination comprising nalbuphine
EP2343045A3 (en) 2003-02-24 2011-09-21 Pharmaceutical Productions Inc. Transmucosal drug delivery system
JP4739217B2 (ja) 2003-05-07 2011-08-03 サムヤン コーポレイション 速く溶ける錠剤を製造するための高可塑性顆粒
US7954491B2 (en) 2003-06-13 2011-06-07 Civitas Therapeutics, Inc. Low dose pharmaceutical powders for inhalations
CN100471497C (zh) 2003-06-25 2009-03-25 中国人民解放军军事医学科学院毒物药物研究所 盐酸纳洛酮鼻粉剂
US20050042178A1 (en) 2003-08-18 2005-02-24 Boehringer Ingelheim International Gmbh Microparticles containing the CGRP-antagonist 1-[N2-[3,5-dibrom-N-[[4-(3,4-dihydro-2(1H)-oxoquinazoline-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazine, process for preparing and the use thereof as inhalation powder
WO2005044186A2 (en) 2003-10-28 2005-05-19 Glaxo Group Limited Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
CN1640402A (zh) 2004-01-02 2005-07-20 广东奇方药业有限公司 一种稳定的纳洛酮粉针剂
IL159729A0 (en) 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents
US8642079B2 (en) 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
CN1615867A (zh) 2004-10-22 2005-05-18 北京阳光润禾科技有限公司 注射用盐酸纳洛酮冻干粉针制剂
WO2006101536A1 (en) 2004-11-04 2006-09-28 Akina, Inc. Fast-melting tablets having taste-masking and sustained release properties
CN1781479B (zh) 2004-12-02 2010-06-30 和记黄埔医药企业有限公司 一种马蔺子素分散体系及其制备方法
US20080317863A1 (en) 2005-02-10 2008-12-25 Christer Nystrom Pharmaceutical Compositions Useful in the Transmucosal Administration of Drugs
KR101233235B1 (ko) 2005-08-26 2013-02-15 에스케이케미칼주식회사 초기 용출율이 개선된 프란루카스트 고체분산체의 약제학적조성물 및 그의 제조방법
US20070202163A1 (en) 2005-09-09 2007-08-30 Mutasem Rawas-Qalaji Fast-disintegrating epinephrine tablets for buccal or sublingual administration
CN1939358A (zh) 2005-09-30 2007-04-04 江西本草天工科技有限责任公司 肿节风分散片
CN1813739A (zh) 2005-11-25 2006-08-09 王颖 一种注射用盐酸纳美芬冻干粉针制剂
CA2640165A1 (en) 2006-01-27 2007-08-02 The Provost, Fellows And Scholars Of The College Of The Holy And Undivid Ed Trinity Of Queen Elizabeth Near Dublin A method of producing porous microparticles
WO2007096906A2 (en) 2006-02-27 2007-08-30 Panacea Biotec Ltd. Novel buccoadhesive compositions and process of preparation thereof
US20100226979A1 (en) 2006-03-21 2010-09-09 Jubilant Organosys Limited Taste Masked Phamaceutical Composition for Oral Solid Dosage form and Process for Preparing the Same Using Magnesium Aluminium Silicate
CN101460150B (zh) 2006-03-31 2014-02-12 鲁比康研究私人有限公司 用于口腔崩解片剂的可直接压片复合物
PL2061427T3 (pl) 2006-09-15 2011-12-30 Echo Pharmaceuticals Bv Granulat zawierający substancję farmaceutycznie aktywną i emulgator oraz sposób jego wytwarzania
US20080269347A1 (en) 2006-09-28 2008-10-30 Azopharma, Inc. Epinephrine formulations
JP2010515753A (ja) 2007-01-10 2010-05-13 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 肺内送達用免疫抑制剤組成物の送達の増強
WO2009040595A1 (en) 2007-09-28 2009-04-02 Wockhardt Research Centre Multi-dose pharmaceutical composition of analgesic for nasal administration
CN102083467B (zh) 2008-03-11 2013-12-25 Aska制药株式会社 固体分散体及其药物组合物、以及它们的制备方法
US20090246256A1 (en) 2008-03-27 2009-10-01 Al-Ghananeem Abeer M Compositions and Methods for Transmucosal Delivery of Lofexidine
US20090264530A1 (en) 2008-04-16 2009-10-22 Nickell Robert P Combined nsaid and acetaminophen formulation and method
US8715715B2 (en) 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
ES2661215T3 (es) 2009-05-20 2018-03-28 Aeras Composiciones víricas; inmunógenas; secadas por pulverización; estables
PL3111927T3 (pl) 2009-05-29 2020-06-29 Pearl Therapeutics, Inc. Kompozycje do wziewnego podawania środków aktywnych oraz związane z nimi sposoby i systemy
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
DK2480197T3 (en) 2009-09-25 2016-01-25 Reddys Lab Ltd Dr Compositions containing triptanforbindelser
RU2013113627A (ru) 2010-08-27 2014-10-10 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтическая композиция и ее введения
CN103200938B (zh) 2010-08-30 2018-07-31 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
MX2013003522A (es) 2010-10-01 2013-05-22 Cipla Ltd Composicion farmaceutica.
CN107028900A (zh) 2010-12-02 2017-08-11 艾戴尔医药公司 快速分散颗粒、口腔崩解片以及方法
DK2675301T3 (en) 2011-02-18 2019-03-25 Biolingus Ip Llc PROCEDURE FOR PRODUCING PRODUCTS CONTAINING STABILIZED ACTIVE SUBSTANCES
MY194947A (en) 2011-05-13 2022-12-27 Euro Celtique Sa Intranasal pharmaceutical dosage forms comprising naloxone
BR112014028431B1 (pt) 2012-05-11 2022-01-11 Activus Pharma Co., Ltd Nanopó de composto orgânico, método para produzir o mesmo e suspensão
EP2861224A4 (en) 2012-06-15 2015-11-18 Univ Nova Southeastern EPINEPHRINNANOPARTICLES, METHOD FOR THE PRODUCTION THEREOF AND METHOD FOR THE USE THEREOF FOR TREATING SUFFERING SUFFERING TO EPINEPHRIN
US9789071B2 (en) * 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
MX2016002705A (es) 2013-09-03 2016-09-06 G2B Pharma Inc Formulacion intranasal para el tratamiento por reanimacion cardiopulmonar (rcp), mantenimiento cardiaco vital (cls), de anafilaxia y/o reacciones anafilactoides.
EP2886107A1 (en) 2013-12-17 2015-06-24 ObsEva S.A. Oral formulations of pyrrolydine derivatives
WO2015095389A1 (en) 2013-12-18 2015-06-25 Aegis Therapeutics, Llc Compositions for drug administration
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
US10085937B2 (en) 2014-03-14 2018-10-02 Adapt Pharma Limited Nasal drug products and methods of their use
US9480644B2 (en) 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
NZ724756A (en) 2014-04-04 2023-07-28 Ai Therapeutics Inc An inhalable rapamycin formulation for treating age-related conditions
US20190008759A1 (en) 2014-07-03 2019-01-10 Darren Rubin Safer and more effective methods of transmucosal delivery for raising blood pressure and stimulating the body
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
EP3174534A1 (en) 2014-08-01 2017-06-07 KRKA, d.d., Novo mesto Pharmaceutical formulation comprising an opioid agonist and an opioid antagonist prepared by melt granulation using lipid esters
WO2016044813A1 (en) * 2014-09-18 2016-03-24 Virun, Inc. Pre-spray emulsions and powders containing non-polar compounds
WO2016055544A1 (en) 2014-10-08 2016-04-14 Eratech S.R.L. Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation
EP3220893B1 (en) 2014-11-14 2023-06-07 Asoltech Srl Composition based on coq10
EP3025705B8 (en) 2014-11-25 2018-11-28 Sanofi Ilaç Sanayi ve Ticaret Anonim Sirketi Stable ivabradine formulations
CN104547220A (zh) 2014-12-30 2015-04-29 陈宏� 一种治疗儿童视觉疲劳的中药组合物及其制剂
US10166197B2 (en) 2015-02-13 2019-01-01 St. John's University Sugar ester nanoparticle stabilizers
BR112017014994B1 (pt) 2015-02-17 2023-12-19 Eli Lilly And Company Composições em pó nasal para tratamento de hipoglicemia, seu uso e seus métodos de preparação, e aplicador nasal
US20170189352A1 (en) 2015-03-13 2017-07-06 Par Pharmaceutical, Inc. Epinephrine formulations
AU2015390471A1 (en) 2015-04-08 2017-11-09 John KLASSEN Pharmaceutical compositions of polyanionic and non-ionic cyclodextrin-based dendrimers and uses thereof
HK1251998A1 (zh) 2015-05-01 2019-05-10 Civitas Therapeutics, Inc. 佐米曲普坦肺部给药粉
US10039710B2 (en) 2015-09-18 2018-08-07 Insys Development Company, Inc. Epinephrine spray formulations
AU2017210319A1 (en) 2016-01-20 2018-08-23 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
ITUB20161027A1 (it) 2016-02-24 2017-08-24 Altergon Sa Preparazioni farmaceutiche oromucosali ad elevata biodisponibilita’ a base di ciclodestrina e sucralosio
WO2017158439A1 (en) 2016-03-16 2017-09-21 Omegatri As Powders and tablets comprising omega-3 fatty acid derivatives and methods for their production
US20170312226A1 (en) 2016-04-28 2017-11-02 Ascent Pharmaceuticals, Inc. Pharmaceutical dosage forms
US11903951B2 (en) 2016-06-03 2024-02-20 M et P Pharma AG Nasal pharmaceutical compositions with a porous excipient
WO2017218918A1 (en) 2016-06-17 2017-12-21 Ys Pharmtech Stabilization of epinephrine formulations
WO2018009532A1 (en) * 2016-07-06 2018-01-11 Mccormick & Company, Incorporated Natural encapsulation flavor products
EP3493789A2 (en) 2016-08-05 2019-06-12 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical powder compositions
JP2020500081A (ja) 2016-09-28 2020-01-09 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． オピオイドを送達する経皮薬剤送達装置
WO2018064672A1 (en) 2016-09-30 2018-04-05 Opiant Pharmaceuticals, Inc. Treatment with intranasal naloxone
CA3043028A1 (en) 2016-11-09 2018-05-17 Opiant Pharmaceuticals, Inc. Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions
IL312012A (en) 2016-11-18 2024-06-01 Opiant Pharmaceuticals Inc Compositions and methods for the treatment of opioid overdose
WO2018148382A1 (en) 2017-02-10 2018-08-16 Mucodel Pharma Llc Chemically stable compositions of a pharmaceutical active agent in a multi-chambered delivery system for mucosal delivery
CN111050760A (zh) 2017-04-17 2020-04-21 希克玛制药美国公司 肾上腺素喷雾制剂
US20180193332A1 (en) 2017-10-09 2018-07-12 Adapt Pharma Operations Limited Low-temperature stable opioid antagonist solutions
WO2019139865A1 (en) 2018-01-10 2019-07-18 Insys Development Company. Inc. Methods of stabilizing epinephrine
WO2019157099A1 (en) 2018-02-06 2019-08-15 Aegis Therapeutics, Llc Intranasal epinephrine formulations and methods for the treatment of disease
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
EP3806827A4 (en) 2018-06-13 2022-03-23 Hikma Pharmaceuticals USA Inc. EPINEPHRINE SPRAY FORMULATIONS
US20230014352A1 (en) 2019-03-29 2023-01-19 The Regents Of The University Of California Inhaled statins as bronchodilators to improve lung function in respiratory diseases
US10729687B1 (en) 2019-07-09 2020-08-04 Orexo Ab Pharmaceutical composition for nasal delivery
FR3098420B1 (fr) 2019-07-10 2021-07-09 Aptar France Sas Dispositif de distribution nasale de poudre
US11400045B2 (en) 2020-03-16 2022-08-02 Nasus Pharma Ltd. Treatment with powdered intranasal epinephrine
PT3962455T (pt) * 2020-05-18 2022-10-13 Orexo Ab Nova composição farmacêutica para entrega de fármacos
FR3121047B1 (fr) 2021-03-29 2023-07-14 Aptar France Sas Dispositif de distribution nasale de poudre
US11617716B2 (en) 2021-06-10 2023-04-04 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods
AR127780A1 (es) * 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702362A (en) 1995-05-26 1997-12-30 Bayer Aktiengesellschaft Nasal applicator
US6398074B1 (en) 1998-03-10 2002-06-04 Valois S.A. Reservoir, reservoir filling method and device for dispensing fluid contained in the reservoir
US6938798B2 (en) 2000-12-08 2005-09-06 Tebro S.A. Fluid or powdery product dispensing device
US20050001411A1 (en) 2001-09-06 2005-01-06 Christian Theiss Method for the determination of parameters of a seat passenger
US8747813B2 (en) 2002-06-28 2014-06-10 Civitas Therapeutics, Inc. Inhalable epinephrine
US7947742B2 (en) 2002-06-28 2011-05-24 Civitas Therapeutics, Inc. Inhalable epinephrine
US8415397B2 (en) 2002-06-28 2013-04-09 Civitas Therapeutics, Inc. Inhalable epinephrine
US7722566B2 (en) 2003-10-09 2010-05-25 Shin Nippon Biomedical Laboratories, Ltd. Device to deliver a powdery medicine into nasal cavity
WO2010142696A1 (en) 2009-06-11 2010-12-16 Charité - Universitätsmedizin Berlin Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
US20110045088A1 (en) 2009-07-31 2011-02-24 Shin Nippon Biomedical Laboratories, Ltd. Intranasal granisetron and nasal applicator
WO2014004400A2 (en) 2012-06-28 2014-01-03 The Governt. Of The Usa As Represented By The Secretary Of The Department Of Health & Human Services Nasal dry powder delivery system for vaccines and other treatment agents
US9724713B2 (en) 2013-07-05 2017-08-08 Aptar France Sas Fluid or powdery product dispensing device
US20180092839A1 (en) 2016-10-03 2018-04-05 Lance L. Gooberman Medicated spray for treatment of substance abuse, overdose, addiction and impulse control disorders
WO2019038756A1 (en) 2017-08-20 2019-02-28 Solubest Ltd. DRY POWDER COMPOSITIONS FOR INTRANASAL DELIVERY
US10653690B1 (en) 2019-07-09 2020-05-19 Orexo Ab Pharmaceutical composition for nasal delivery

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"Aulton's Pharmaceutics: The Design and Manufacture of Medicines", 2017, ELSEVIER
"Remington: The Science and Practice of Pharmacy", 2020, PHARMACEUTICAL PRESS
"The HLB System: A Time-Saving Guide to Emulsifier Selection", 1976, ICI AMERICAS INC, pages: 20 - 21
BERTAN ET AL., EUR. J. PHARM. SCI., vol. 27, 2006, pages 62
GANDHI, ADVANCED DRUG DELIVERY REVIEWS, vol. 43, 1994, pages 67
J. DRUG DELIVERY, 2018, pages 1 - 19
KOUZHOU ET AL.: "Amorphous Solid Dispersions", 2014, SPRINGER
LACHMAN ET AL.: "The Theory and Practice of Industrial Pharmacy", 2015, CBS
RUSSO ET AL., J. PHARM. SCI., vol. 95, 2006, pages 2253
SHOJAEI, J. PHARM. PHARMACEUTICAL SCI., vol. 15, 1998, pages 19
VENGEROVICH ET AL., BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, vol. 163, 2017, pages 737

Also Published As

Publication number Publication date
JP2024542520A (ja) 2024-11-15
AU2022395916A1 (en) 2024-05-30
CA3238847A1 (en) 2023-06-01
MX2024006403A (es) 2024-08-15
CN118678979A (zh) 2024-09-20
WO2023094816A1 (en) 2023-06-01
KR20240111769A (ko) 2024-07-17
EP4237051A1 (en) 2023-09-06
US12303472B2 (en) 2025-05-20
CN118695851A (zh) 2024-09-24
IL313014A (en) 2024-07-01
US20250262174A1 (en) 2025-08-21
US20230310349A1 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
IL291155A (en) Drug delivery device
IL291415A (en) Drug delivery device
IL326743A (en) Drug delivery device
IL291295A (en) Drug delivery device
GB2572126B (en) Pharmaceutical
GB2569961B (en) Pharmaceutical
GB2572125B (en) Pharmaceutical
IL291154A (en) Drug delivery device
GB202117016D0 (en) New pharmaceutical device
CA225821S (en) Dermaplaning device
GB201909984D0 (en) Medical device
CA210949S (en) Dermaplaning device
PL4003293T3 (pl) Rozwój farmaceutyczny
GB202006067D0 (en) Device
GB202015727D0 (en) Syringe device
EP4011349C0 (en) MEDICATION DOSING DEVICE
CA210151S (en) Pharmaceutical training device
GB2610068B (en) Therapeutic device
GB202113078D0 (en) New pharmaceutical use
GB202014420D0 (en) New pharmaceutical use
GB201916808D0 (en) Pharmaceutical delivery device
CA205986S (en) Vaping device
EP4455381A4 (en) CHAIN FEEDING DEVICE
GB202011563D0 (en) New medical device
GB201917327D0 (en) New pharmaceutical use

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)